ethyl 3-(benzyl(ethyl)amino)propanoate | 1094629-96-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-(benzyl(ethyl)amino)propanoate
• 英文别名: Ethyl 3-[benzyl(ethyl)amino]propanoate
• CAS: 1094629-96-5
• 化学式: C₁₄H₂₁NO₂
• mdl: MFCD11651286
• 分子量: 235.326
• InChiKey: YZFJTMSSZWULHK-UHFFFAOYSA-N

物化性质

• 沸点：
  311.9±25.0 °C(Predicted)
• 密度：
  1.014±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-(benzyl(ethyl)amino)propanoate 在 lithium aluminium tetrahydride 、 氢溴酸 、 三乙胺 、 苯酚 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 反应 49.0h， 生成 tert-butyl (3-((3-(benzyl(ethyl)amino)propyl)(tert-butoxycarbonyl)amino)propyl)(3-((tert-butoxycarbonyl)(ethyl)amino)propyl)carbamate
  参考文献：
  名称：

  Bisethylnorspermine Lipopolyamine as Potential Delivery Vector for Combination Drug/Gene Anticancer Therapies

  摘要：

  设计一种新型合成基因递送系统，其中载体分子同时作为载体和靶向癌症中失调的多胺代谢的细胞毒剂。合成了双乙基诺瑟普明（BENSpm）脂质聚胺，并通过MTS检测评估了其在MCF-7和MCF-10A细胞中的毒性。通过使用荧光素酶质粒DNA确定转染活性。采用亲核环开的方法合成了多胺抗癌药物BENSpm的不对称脂质类似物。合成的LipoBENSpm在MCF-7人乳腺癌细胞系中显示出与母体BENSpm相当的细胞毒性，但介导的转染活性高出3至4个数量级。重要的是，BENSpm的细胞静止活性通常在低微摩尔（μM）范围内，符合有效基因递送所需的相关且典型的浓度范围。这些发现使得基于BENSpm的基因递送载体成为癌症治疗中联合药物/基因方法的有希望的候选者。

  DOI：

  10.1007/s11095-010-0197-4
• 作为产物：
  描述：

  N-乙基苄胺 以76 %的产率得到ethyl 3-(benzyl(ethyl)amino)propanoate
  参考文献：
  名称：

  DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORS

  摘要：

  A disulfiram derivative of formula (I) wherein R 1 and R 2 are independently —CH 2 CH 2 COOH, —CH 2 CH 2 COOEt, optionally substituted methylenepyridyl, optionally substituted methylenefuranyl, or optionally substituted methylenethiopenyl, may be useful in aldehyde dehydrogenase 1 a 1 (ALDH 1 a 1 ) and/or monoacylglycerol lipase (MAGL)-mediated diseases or disorders. Such derivatives may avoid or limit aldehyde dehydrogenase 2 (ALDH2) and/or fatty acid amide hydrolase (FAAH) antagonism.

  公开号：

  US20230174475A1

文献信息

• New Disulfiram Derivatives as MAGL-Selective Inhibitors
  作者：Ziad Omran

  DOI：10.3390/molecules26113296

  日期：——

  2-arachidonoyl glycerol (2-AG) to arachidonic acid (AA), a precursor of prostaglandin synthesis. The inhibition of MAGL activity would be beneficial for the treatment of a wide range of diseases, such as inflammation, neurodegeneration, metabolic disorders and cancer. Here, the author reports the pharmacological evaluation of new disulfiram derivatives as potent inhibitors of MAGL. These analogues displayed high

  单酰基甘油脂肪酶 (MAGL) 是人类内源性大麻素系统中的关键酶。它也是负责将 2-花生四烯酸甘油 (2-AG) 转化为花生四烯酸 (AA)（前列腺素合成的前体）的主要酶。MAGL 活性的抑制将有利于治疗多种疾病，例如炎症、神经变性、代谢紊乱和癌症。在这里，作者报告了新的双硫仑衍生物作为 MAGL 的有效抑制剂的药理学评价。这些类似物对脂肪酸酰胺水解酶 (FAAH)（另一种内源性大麻素水解酶）显示出高抑制选择性。特别是，化合物2i在低微摩尔范围内抑制 MAGL。然而，它没有显示任何对 FAAH 的抑制活性。
• Methods and compounds for treating depression and other disorders
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1790337A2

  公开（公告）日：2007-05-30

  The present invention features compounds active at both the serotonin reuptake site and the N-methyl-D-aspartate (NMDA) receptor and the use of such compounds for treating different disorders. Compounds having activity at the serotonin reuptake site and the NMDA receptor ("multi-active compounds") can be used to treat different types of disorders such as obsessive-compulsive disorders (OCD), sleep disorders, sexual dysfunction, and eating disorders.

  本发明的特点是具有在血清素再摄取位点和N-甲基-D-天门冬氨酸（NMDA）受体活性的化合物，并使用这些化合物治疗不同的疾病。具有在血清素再摄取位点和NMDA受体（“多功能化合物”）的活性的化合物可用于治疗不同类型的疾病，如强迫症障碍（OCD），睡眠障碍，性功能障碍和进食障碍。
• Crf Receptor Antagonists and Methods
  申请人：Luo Zhiyong

  公开号：US20070293511A1

  公开（公告）日：2007-12-20

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了具有治疗多种疾病的用途的CRF受体拮抗剂，包括治疗在恒温动物中表现为CRF过度分泌的疾病，如中风。本发明的CRF受体拮抗剂具有以下结构：包括立体异构体、前药和药学上可接受的盐，其中R1、R2、R3、Y、Ar和Het的定义如本文所述。还揭示了含有CRF受体拮抗剂和药学上可接受的载体的组合物，以及使用它们的方法。
• Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating
  申请人：NeuroSolis, Inc.

  公开号：US20180099956A1

  公开（公告）日：2018-04-12

  The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.
• Bisethylnorspermine Lipopolyamine as Potential Delivery Vector for Combination Drug/Gene Anticancer Therapies
  作者：Yanmei Dong、Jing Li、Chao Wu、David Oupický

  DOI：10.1007/s11095-010-0197-4

  日期：2010.9

  To design novel synthetic gene delivery system in which the carrier molecule functions dually as a carrier and a cytotoxic agent targeting dysregulated polyamine metabolism in cancer. Bisethylnorspermine (BENSpm) lipopolyamine was synthesized and its toxicity evaluated by MTS assay in MCF-7 and MCF-10A cells. Transfection activity was determined using luciferase plasmid DNA. Asymmetrical lipid analogue of polyamine anticancer drug BENSpm was synthesized using nucleophilic ring opening of azetidinium ion. The synthesized LipoBENSpm showed cytotoxicity comparable to that of parent BENSpm in human breast cancer cell line MCF-7 but mediated 3–4 orders magnitude higher transfection activity. Importantly, cytostatic activity of BENSpm, typically in a low μM range, falls within a relevant and typical concentration range required for efficient gene delivery. These findings make gene delivery vectors based on BENSpm promising candidates for combination drug/gene approaches to the treatment of cancer.

  设计一种新型合成基因递送系统，其中载体分子同时作为载体和靶向癌症中失调的多胺代谢的细胞毒剂。合成了双乙基诺瑟普明（BENSpm）脂质聚胺，并通过MTS检测评估了其在MCF-7和MCF-10A细胞中的毒性。通过使用荧光素酶质粒DNA确定转染活性。采用亲核环开的方法合成了多胺抗癌药物BENSpm的不对称脂质类似物。合成的LipoBENSpm在MCF-7人乳腺癌细胞系中显示出与母体BENSpm相当的细胞毒性，但介导的转染活性高出3至4个数量级。重要的是，BENSpm的细胞静止活性通常在低微摩尔（μM）范围内，符合有效基因递送所需的相关且典型的浓度范围。这些发现使得基于BENSpm的基因递送载体成为癌症治疗中联合药物/基因方法的有希望的候选者。